| Metric | Value (₹ Cr) | Q2 FY26 | Q3 FY25 |
|---|---|---|---|
| Revenue | 77.42 | 9.1% | 22.5% |
| Total Income | 78.08 | 3.2% | 9.9% |
| Expenditure | 65.88 | 0.1% | 12.3% |
| PBT | 12.21 | 18.0% | 1.5% |
| Net Profit | 9.31 | 35.0% | 18.4% |
| OPM | 22.98% | 6.47pp | 16.49pp |
| NPM | 11.92% | 5.84pp | 2.77pp |
| EPS | 10.94 | 35.1% | 18.4% |
Hester Biosciences Q3 and 9M FY26 Results: Standalone Revenue up 12%, Profit up 140% | Consolidated Revenue up 1%, Profit up 50%
30 Jan 2026 · 30 Jan, 11:51 am
Summary
Hester Biosciences has announced its unaudited financial results for Q3 and 9M FY26. The Poultry Healthcare Division showed a significant growth, while the Animal Healthcare Division faced a decline due to delays in government-led immunisation programmes. The company received a regulatory milestone with the marketing and manufacturing licenses for the H9N2 Avian Influenza vaccine.
Key Highlights
- 1
Standalone Q3 Revenue up 12%
- 2
Standalone Profit up 140%
- 3
9M Standalone Revenue down 5%
- 4
9M Standalone Profit up 16%
- 5
Consolidated Q3 Revenue up 22%
- 6
Consolidated Q3 Profit down 18%
- 7
9M Consolidated Revenue up 1%
- 8
9M Consolidated Profit up 50%
- 9
Poultry Healthcare Division grew by 32% in Q3 FY26
- 10
Animal Healthcare Division declined by 38% in Q3 FY26
- 11
H9N2 Avian Influenza vaccine received marketing and manufacturing licenses
Management Comments
Rajiv Gandhi
Not provided in the document.
Informational and educational content only. Not investment advice.